DexCom (DXCM) stock-based compensation was $160M in FY2025 (-6% YoY). The tables below show the complete quarterly and annual stock-based compensation history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Stock-Based Compensation
Fiscal Year
Stock-Based Compensation
YoY
2025
$160M
-6%
2024
$170M
+13%
2023
$151M
+19%
2022
$126M
+12%
2021
$113M
-5%
2020
$119M
+16%
2019
$103M
+1%
2018
$102M
-4%
2017
$106M
-4%
2016
$111M
+34%
2015
$83M
+65%
2014
$50M
+103%
2013
$25M
+34%
2012
$18M
+36%
2011
$14M
+44%
2010
$9M
+12%
2009
$8M
Recent Quarterly Stock-Based Compensation
Quarter
Stock-Based Compensation
Q1 2026
$43M
Q4 2025
$35M
Q3 2025
$45M
Q2 2025
$45M
Q1 2025
$34M
Q4 2024
$43M
Q3 2024
$43M
Q2 2024
$45M
Q1 2024
$39M
Q4 2023
$37M
Q3 2023
$39M
Q2 2023
$40M
Source: DXCM on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.